Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500 subject open label study as part of an FDA requirement for Androxal, and it's sent a "request for guidance" letter to the agency regarding two other pivotal studies on the drug as well. Additionally, the company also says its requested an end of Phase 2 meeting before the end of April for its vaginal Proellex program for the treatment of uterine fibroids.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs